Crinetics discloses non-compete deals with executives tied to Vertex merger

Crinetics Pharmaceuticals disclosed in an 8-K filing that on July 6, 2026, it signed non-compete agreements with several top executives in connection with its pending merger with Vertex Pharmaceuticals. The agreement was tied to a Merger Agreement dated the same day among Crinetics, Vertex Pharmaceuticals Incorporated, and Clark Merger Sub, Inc., a Vertex subsidiary that will merge into Crinetics, leaving Crinetics as a wholly owned subsidiary of Vertex.¹ The named executives are R. Scott Struthers, President and CEO, along with CFO Tobin Schilke, Chief Scientific Officer Stephen Betz, and Chief Commercial Officer Isabel Kalofonos.

Under the agreements, each executive agreed not to work in any capacity for specified competing businesses, in territories where Crinetics operates, for one year starting from the date the merger closes.¹ In exchange, Schilke, Betz, and Kalofonos will receive cash payments of $140,000, $30,000, and $30,000, respectively, once the merger closes.¹ The filing does not mention a payment tied to Struthers' agreement.

Crinetics said the full text of the non-compete agreements will appear as an exhibit in a future quarterly filing, specifically the company's Form 10-Q covering the period ending September 30, 2026.¹

The filing also noted procedural next steps for the merger. A stockholder meeting will be announced to seek approval for the transaction, and Crinetics plans to file related materials with the SEC, including preliminary and definitive proxy statements.¹ The definitive proxy statement will eventually be mailed to Crinetics shareholders.¹ The company reiterated standard cautionary language about forward-looking statements and risks tied to the deal's completion, regulatory approval, and integration.